Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents Awarded to Alnylam, Merck, Alcon

Premium

Title: Hepatitis C dsRNA Effector Molecules, Expression Constructs, Compositions, and Methods of Use

Patent Number: 8,614,198

Filed: June 28, 2008

Lead Inventor: Daniel McCallus, Alnylam Pharmaceuticals


Title: Double-stranded RNA Director to CASP2 and Methods of Use Thereof

Patent Number: 8,614,309

Filed: Sept. 4, 2008

Lead Inventor: Elena Feinstein, Quark Pharmaceuticals


Title: Devices, Systems, and Methods for Improving Memory and/or Cognitive Function through Brain Delivery of siRNA

Patent Number: 8,618,069

Filed: Oct. 8, 2009

Lead Inventor: William Kaemmerer, Medtronic


Title: RNA Interference-mediated Inhibition of Gene Expression using Chemically Modified Short Interfering Nucleic Acid

Patent Number: 8,618,277

Filed: May 25, 2012

Lead Inventor: Leonid Beigelman, Merck


Title: RNAi-mediated Inhibition of Histamine Receptor H1-related Conditions

Patent Number: 8,618,278

Filed: June 11, 2012

Lead Inventor: John Yanni, Alcon

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.